安科生物(300009.SZ):擬轉讓餘良卿藥業31.72%股權用於股權激勵
格隆匯7月13日丨安科生物(300009.SZ)公佈,公司本着“聚焦主業、激發活力”的原則,為充分調動公司全資子公司安徽安科餘良卿藥業有限公司(“餘良卿藥業”)管理層及核心骨幹的工作積極性,維護餘良卿藥業的長期穩定發展,進一步建立、健全長效激勵機制,公司擬轉讓餘良卿藥業31.72%股權(對應註冊資本人民幣1,903萬元)用於股權激勵。
此次股權激勵的對象由餘良卿藥業的執行董事、高級管理人員、其他核心員工構成,上述激勵對象將通過安慶卿鴻股權投資合夥企業(有限合夥)(“卿鴻投資”)、安慶卿眾股權投資合夥企業(有限合夥)(“卿眾投資”)、安慶卿喆股權投資合夥企業(有限合夥)(“卿喆投資”)(以下合稱“餘良卿員工持股平台”)(上述合夥企業名稱均為暫定名,以工商行政管理部門核准登記為準)間接持有餘良卿藥業股權,餘良卿藥業的執行董事、總經理嚴新文除通過上述餘良卿員工持股平台間接持有餘良卿藥業股權外,還將直接持有餘良卿藥業股權。
此次股權轉讓暨激勵事項完成後,公司持有餘良卿藥業的股權比例由100%變更為68.28%,餘良卿藥業仍為公司合併報表範圍內的控股子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.